Recursion Pharmaceuticals, Inc. (RXRX) Stock
NASDAQ · RXRX
3.80
Fundamentals
Market cap
$2.01B
Price / Earnings ratio
-4.1x
Price / Sales ratio
38.4x
Price / Book ratio
2.3x
Return on assets
-41.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
NeutralRXRXSeptember 24, 2026
Zacks Investment ResearchNeutral
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX

Business Wire
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
NeutralRXRXSeptember 21, 2026
Business WireNeutral
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
RXRX

MarketBeat
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
NeutralRXRXSeptember 21, 2026
MarketBeatNeutral
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
RXRX

Zacks Investment Research
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
NeutralRXRXSeptember 16, 2026
Zacks Investment ResearchNeutral
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
RXRX
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
90M59M30M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
2B1B584M0
Revenue to Profit
2025$74.7M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-644.8M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.27
Q1FY26
$-0.17
Q2FY26
The market is expecting earnings per share of -$0.17 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
NeutralRXRXSeptember 24, 2026
Zacks Investment ResearchNeutral
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX

Business Wire
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
NeutralRXRXSeptember 21, 2026
Business WireNeutral
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
RXRX

MarketBeat
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
NeutralRXRXSeptember 21, 2026
MarketBeatNeutral
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
RXRX

Zacks Investment Research
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
NeutralRXRXSeptember 16, 2026
Zacks Investment ResearchNeutral
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
RXRX

Zacks Investment Research
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
NeutralRXRXSeptember 10, 2026
Zacks Investment ResearchNeutral
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
RXRX

The Motley Fool
2 Beaten-Down Stocks to Avoid Right Now
NeutralRXRXSeptember 8, 2026
The Motley FoolNeutral
2 Beaten-Down Stocks to Avoid Right Now
RXRX

Zacks Investment Research
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
NeutralRXRXSeptember 4, 2026
Zacks Investment ResearchNeutral
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
RXRX

Zacks Investment Research
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
NeutralRXRXSeptember 3, 2026
Zacks Investment ResearchNeutral
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
RXRX

Zacks Investment Research
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
NeutralRXRXAugust 17, 2026
Zacks Investment ResearchNeutral
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RXRX

MarketBeat
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
NeutralRXRXAugust 17, 2026
MarketBeatNeutral
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
RXRX
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
SectorHealthcare
IndustryBiotechnology
Employees600
CEODr. Najat Khan Ph.D.
IPO DateApr 15, 2021
HeadquartersSalt Lake City, UT
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Najat Khan Ph.D. | CEO, President & Director | 1984 |
| Mr. Ben R. Taylor | CFO & President of Recursion UK | 1977 |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer | 1983 |
| Dr. David Hallett Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Nathan Hatfield J.D., M.B.A. | Chief Legal Officer & Corporate Secretary | — |
| Mr. Ryan Kelly | Chief Communications Officer | — |
| Ms. Erica Fox | Chief People and Impact Officer | — |
| Mr. Matthew Kinn M.B.A. | Chief Business Officer | — |
| Mr. Sid Jain | Senior Vice President of Clinical Development & Data Science | — |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer | 1971 |
Fundamentals
Valuation
Market cap$2.01B
Price-to-sales ratio38.36
Price-to-book value2.30
Price-earnings ratio-4.10
Return on Equity-54.00%
Return on Sales-850.00%
Return on Assets-41.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.00
Income Statement
Average volume19,236,838
EBITDA$-458.95M
1 year high (52w)$7.18
1 year low (52w)$2.77
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.2 | -12.4 | -5.3 | -2.0 | ||||||||
| 2022 | -34.3 | -11.4 | -33.5 | -19.4 | -7.4 | +35.0 | +0.4 | +26.6 | -2.2 | -2.9 | -10.9 | -17.1 |
| 2023 | +10.3 | -4.7 | -16.1 | -30.8 | +83.1 | -14.8 | +91.3 | -37.0 | -16.1 | -26.3 | +34.6 | +33.4 |
| 2024 | -4.7 | +40.9 | -22.2 | -16.5 | -0.7 | -12.7 | +9.9 | -0.8 | +8.6 | +2.4 | +10.5 | -10.8 |
| 2025 | +0.4 | +3.6 | -19.7 | +9.6 | -24.0 | +15.8 | +16.0 | -17.3 | +4.7 | +8.2 | -14.9 | -6.2 |
| 2026 | -0.2 | -12.2 | -15.4 | +13.1 | +5.9 | -3.2 | -18.3 | +6.9 | +12.3 |



